GSK statement regarding 2010 Nature Medicine study

June 10, 2013

GSK and Nature Medicine recently became aware of allegations of misrepresentation of data in a research paper written by scientists at GSK’s China research centre and published in Nature Medicine in 2010*. The published study was from preclinical, early stage research and did not directly involve patients. 

The integrity of our research is critical to our work and when these allegations came to light we immediately contacted the journal to tell them that we were taking the charges seriously and would be investigating thoroughly. Regretfully, our investigation has established that certain data in the paper were indeed misrepresented. We’ve shared our conclusion that the paper should be retracted and are in the process of asking all of the authors to sign a statement to that effect, according to Nature Medicine’s procedure.             

We have taken action in response to these findings, which we have shared with our employees. One individual has been dismissed from GSK; a second has submitted his resignation and three others have been placed on administrative leave, pending a final review.

We are committed to the highest ethical and scientific standards and regulators, physicians and patients can have confidence in the research we carry out.  

* "Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease," published in Nature Medicine, 2010, 16: 191-197

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

GlaxoSmithKline Enquiries:

 

 

 

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)

 

Simon Steel

+44 (0) 20 8047 5502

(London)

 

David Daley

+44 (0) 20 8047 5502

(London)

 

Catherine Hartley

+44 (0) 20 8047 5502

(London)

 

 

 

 

US Media enquiries:

Stephen Rea

+1 215 751 4394

(Philadelphia)

 

Melinda Stubbee

+1 919 483 2510

(North Carolina)

 

     

 

   

 

 

     

 

 

 

 

Analyst/Investor enquiries:

Ziba Shamsi

+ 44 (0) 20 8047 3289

(London)

 

Lucy Budd

+44 (0) 20 8047 2248

(London)

 

Tom Curry

+ 1 215 751 5419

(Philadelphia)

 

Gary Davies

+ 44 (0) 20 8047 5503

(London)

 

James Dodwell

+ 44 (0) 20 8047 2406

(London)

 

Jeff McLaughlin

+ 1 215 751 7002

(Philadelphia)

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.